| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V40128-1mg |
≥99% | ￥780.00 |
货期：3-5天 | - | - | - | - |
|
V40128-5mg |
≥99% | ￥1730.00 |
货期：3-5天 | - | - | - | - |
|
V40128-10mg |
≥99% | ￥2740.00 |
货期：3-5天 | - | - | - | - |
|
V40128-25mg |
≥99% | ￥4730.00 |
货期：3-5天 | - | - | - | - |
|
V40128-50mg |
≥99% | ￥6430.00 |
货期：3-5天 | - | - | - | - |
|
V40128-100mg |
≥99% | ￥8670.00 |
货期：3-5天 | - | - | - | - |
|
V40128-200mg |
≥99% | ￥11600.00 |
货期：3-5天 | - | - | - | - |
|
| 体内研究： | The pharmacokinetics of AzddMeC are characterized following intravenous and oral administration of 60 mg/kg of the compound to male rhesus monkeys. 3'-azido-3'-deoxythymidine (AZT) is a major metabolite of AzddMeC in monkeys. AzddMeC concentrations in serum declined rapidly in a biexponential fashion with the terminal half-life ranging from 0.5 to 1.3 hr. Renal excretion of unchanged nucleoside and metabolic deamination yielding AZT are the primary routes of AzddMeC clearance. The oral bioavailability is 26%. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 参考文献： | 1. R F Schinazi, et al. Antiretroviral Activity, Biochemistry, and Pharmacokinetics of 3'-azido-2',3'-dideoxy-5-methylcytidine. Ann N Y Acad Sci. 1990;616:385-97. 2. Boudinot FD, et al. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys. Drug Metab Dispos. 1993;21(5):855‐860. |
||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京